Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675 1683
This examiner grants 56% of resolved cases
Erinne R. Dabkowski is an examiner in Tech Center 1600 and Art Unit 1654 with 716 resolved cases. Her allowance rate is 55.9%, but the interview lift is 69.0%. This suggests that interviews are effective and should be a strategy for applicants. This 69.0% lift is based on 716 resolved cases, making it a strong indicator of potential success in her docket.
The median days to allowance is 1055, providing a timeline for prosecution in Tech Center 1600. Practitioners should use the 69.0% lift to overcome the 55.9% baseline allowance rate, as it represents an increase in the probability of a grant. For the 716 resolved cases, the 1055-day median pendency is a metric for managing client expectations. The data shows that interviews are an impactful tactic available when working with this examiner in Art Unit 1654.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | Final Rejection | Novo Nordisk A/S |
| 18313856 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | Final Rejection | The Regents of the University of Michigan |
| 18163773 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17266897 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Final Rejection | Ohio State Innovation Foundation |
| 18428102 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 18199523 | COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 16954694 | COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17782508 | VEGF MINI-TRAPS AND METHOD OF USE THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17925455 | Methods and Compositions for Treatment of Age-Related Dysfunction | Non-Final OA | The University of Tokyo |
| 17283315 | Selective Binding and Aggregation of Human Keratin in the Skin Barrier Using Human Filaggrin Subdomains SD67 and SD150 | Final Rejection | YALE UNIVERSITY |
| 17672438 | COMPOSITIONS AND METHODS FOR INHIBITING BIOFILM DEPOSITION AND PRODUCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 16771641 | METHOD OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) WITH ROMIPLOSTIM | Non-Final OA | AMGEN INC. |
| 18572462 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | Non-Final OA | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 18441563 | POLYPEPTIDE FOR RESISTING NOVEL CORONAVIRUS AND APPLICATION THEREOF | Non-Final OA | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES |
| 17630747 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | Final Rejection | BicycleTx Limited |
| 17996256 | COMPOSITIONS AND METHODS FOR TREATING HAIR FOLLICLE-LINKED CONDITIONS | Non-Final OA | Henlez APS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy